




Searching News Database: Immune Globulin
HSMN NewsFeed - 1 Sep 2016
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
HSMN NewsFeed - 25 Jun 2012
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
Baxter Announces FDA Approval for GAMMAGARD LIQUID as a Treatment for Multifocal Motor Neuropathy
HSMN NewsFeed - 1 Dec 2010
Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex(R) for Fast Track Development
Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex(R) for Fast Track Development
HSMN NewsFeed - 16 Mar 2009
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
Data Presented at AAAAI Reinforce Baxter's Commitment to Making GAMMAGARD LIQUID Therapy More Convenient
HSMN NewsFeed - 11 Aug 2008
Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
HSMN NewsFeed - 8 May 2008
FDA Grants Priority Review of Gamunex(R) as a Treatment for Neurological Disorder CIDP
FDA Grants Priority Review of Gamunex(R) as a Treatment for Neurological Disorder CIDP
HSMN NewsFeed - 16 Nov 2007
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
HSMN NewsFeed - 14 Nov 2007
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO
HSMN NewsFeed - 2 May 2007
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
HSMN NewsFeed - 16 Jan 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
HSMN NewsFeed - 2 Jan 2007
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
Hospitals, Healthcare Providers to Save with Premier Plasma Distribution Agreement with FFF Enterprises
HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
HSMN NewsFeed - 16 Oct 2006
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
HSMN NewsFeed - 12 Oct 2006
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
HSMN NewsFeed - 29 Jun 2006
Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir(R) in Europe
Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir(R) in Europe
HSMN NewsFeed - 9 Mar 2006
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX(R)
Nabi Biopharmaceuticals Announces U.S. Fast Track Designation for NicVAX(R)
HSMN NewsFeed - 24 Feb 2006
Premier's New Plasma and Recombinant Program Helps Hospitals Acquire Products in Short Supply
Premier's New Plasma and Recombinant Program Helps Hospitals Acquire Products in Short Supply
HSMN NewsFeed - 30 Jan 2006
Nabi Biopharmaceuticals' Mark L. Smith Resigns as Company's CFO, Effective on or Around March 1, 2006
Nabi Biopharmaceuticals' Mark L. Smith Resigns as Company's CFO, Effective on or Around March 1, 2006
HSMN NewsFeed - 27 Jan 2006
MedAssets Names Blood Diagnostics, Inc. as an Awarded Blood Fraction Distributor
MedAssets Names Blood Diagnostics, Inc. as an Awarded Blood Fraction Distributor
HSMN NewsFeed - 25 Jan 2006
Nabi Biopharmaceuticals Provides Update on Strategic Direction of NicVAX(TM) Program
Nabi Biopharmaceuticals Provides Update on Strategic Direction of NicVAX(TM) Program
HSMN NewsFeed - 25 Jan 2006
Baxter Receives Marketing Authorization From the European Commission for KIOVIG to Treat Immunodeficiencies
Baxter Receives Marketing Authorization From the European Commission for KIOVIG to Treat Immunodeficiencies
Additional items found! 68

Members Archive contains
68 additional stories matching:
Immune Globulin
(Password required)
Immune Globulin
(Password required)